NCT07038070

Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study

A Randomized Controlled Trial Comparing the Efficacy of Topical Vaginal Estrogen Versus Topical Vaginal Estrogen Plus Via, a Hyaluronic Acid-Based Vaginal Moisturizer, in the Treatment of Genitourinary Syndrome of Menopause

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 196 (estimated)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: Female
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate whether the administration of vaginal estrogen along with Via, a hyaluronic acid-based vaginal moisturizer, offers superior relief from symptoms of genitourinary syndrome of menopause (GSM) in the urogynecologic patient population, compared to administration of vaginal estrogen alone.

Conditions

• Genitourinary Syndrome of Menopause (GSM)

Interventions

Type	Name	Description
DRUG	Vaginal estrogen tablet	The dosage of the vaginal estrogen will be one 10mcg tablet administered vaginally nightly for 2 weeks, then administered vaginally twice weekly for 14 weeks.
DEVICE	Via Solv Wellness (Hyaluronic Acid Therapy)	The dosage of Via will be a pea-sized amount applied vaginally along the vaginal and vulvar walls nightly for 16 weeks.

Timeline

• Start date: 2025-07-01
• Primary completion: 2026-05-01
• Completion: 2026-05-01
• First posted: 2025-06-26
• Last updated: 2025-06-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study